Gland Pharma reported a strong Q3 FY26, beating estimates on profit and revenue, led by robust growth across key markets, steady margins and momentum in launches and filings.
Gland Pharma reported a strong Q3 FY26, beating estimates on profit and revenue, led by robust growth across key markets, steady margins and momentum in launches and filings.